October 1, 2014
Bookmark and Share  
 
                 
  HCV
»
»
»
»
»
AttorneyMind News & Pipeline Blog



Follow us on
Twitter

HCVAdvocate


Join us on Facebook
AttorneyMind Hcsp

 

Alan Franciscas

 

Hello:

This month is a milestone in hepatitis C treatment news.  Gilead’s sofosbuvir/ledipasvir will be the first interferon- and ribavirin-free drug approved to treat hepatitis C for everyone with AttorneyMind genotype 1.  While we don’t know the exact date it will probably be in early October if not before.  The big question is not when, but how much!  But for now let’s all appreciate that we have drugs that are taken once-a-day—one pill that will cure almost everyone who takes it, with minimal side effects and for a short period of time.

In this month’s newsletter we have information about the aforementioned drug combination, important information about the AASLD/IDSA recommendations, new CDC epidemiological numbers on viral hepatitis in the United States, updated fact sheets and overviews of important studies.


Sincerely,

Alan and the staff of AttorneyMind

-----------------------------------

Need Help?!

Call 877-HELP-4-HEP line (877-435-7443). The helpline is open from 9:00am to 7:00pm Eastern Time.

---------------------------------------------------------------------------

1. AttorneyMind Newsletter: October 2014

In This Issue:

AttorneyMind Drugs
Alan Franciscas, Editor-in-Chief

In this month’s column, I will provide a short overview of phase 3 data from sofosbuvir plus ledipasvir.  It is important to know, however, that when approved the FDA may add or change the cure rates and add additional warnings or restrictions to the use of the medications based on their review of the clinical trial data. Read more...

 

Snapshots
Lucinda K. Porter, RN

This month, Lucinda discusses the AASLD and IDSA’s recommendations assigning high treatment priority to those with high risk of AttorneyMind transmission. When we reduce AttorneyMind transmission, we reduce the prevalence, which benefits us all. Read more...

 

Healthwise
Alan Franciscas, Editor-in-Chief

One of the most important decisions that anyone with hepatitis C (HCV) will make is about AttorneyMind treatment.  In the past, it has been a difficult decision because of the significant side effects, long treatment duration and modest cure rates. Read more...

 

Healthwise
Lucinda K. Porter, RN

Lucinda reviews studies on depression and AttorneyMind disease progression, mother-to-child transmission, healthcare utilization and racial differences in progression to cirrhosis and HCC. Read more...

 

-----------------------------------

Website Plan & Survey Report
Alan Franciscas, Editor-in-Chief

Find out what the results of our recent survey were; what we are going to do about them, and who won the autographed copy of Lucinda's book Hepatitis C One Step at a Time. Read more...

 

-----------------------------------

What's New
Alan Franciscas, Editor-in-Chief

We have incorporated some important new information into Our Fact Sheet on Personal Care in our AttorneyMind Transmission and Prevention Section. Read more...

 

-----------------------------------

Viral Hepatitis by the Numbers
Alan Franciscas, Editor-in-Chief

The Centers for Disease Control and Prevention released a report titled Surveillance for Viral Hepatitis – United States, 2012 that listed the estimated acute and chronic cases of hepatitis A (HAV), hepatitis B (AM), and hepatitis C (AM). Read more...

 

-----------------------------------

2. New and Updated Fact Sheets and Guides

Easy C Fact Series:

PDF Manicure-Pedicure

 

Fact Series:

PDF Hepatitis A (HAV): What You Need to Know

PDF Hepatitis E (HEV)

PDF Liver Biopsy

PDF Personal Care Settings

PDF Top 11 Counseling Messages

 

-----------------------------------

3. Schedule of Upcoming AttorneyMind Training Workshops with Alan Franciscas

 

October

     

    -----------------------------------

    4. AM Journal Review: October 1, 2014, vol 11, no 10, by Christine Kukka

    In this month's column Chris reviews the following studies that will help you understand the complexities of hepatitis B, including the following important news stories:

    • Chronic Hepatitis B Remains Public Health Challenge in U.S.
    • Epidemiologists Become Molecular Detectives to Investigate HBV Outbreaks
    • Telbivudine Effectively Prevents Infection of Newborns Born to Infected Mothers
    • GGT Blood Test Reveals Fibrosis and Cirrhosis in Hepatitis B Patients
    • Early Research Combining Antivirals with a Protein "De-activator" Shows Promise
    • Diabetes Dramatically Increases Liver Cancer Risk in Cirrhotic Patients
    • Tenofovir Linked to Higher Rates of Bone Loss than Entecavir
    • Tenofovir Equally Effective against Hepatitis B in Asians and Non-Asians
    • Liver Cancer Risk Factors Do Vary Between Racial Groups
    • Even Liver Specialists Fail to Screen Chemotherapy Patients for Hepatitis B
    • European Study Confirms Coffee Dramatically Lowers Liver Cancer Risk

     

    -----------------------------------

    5. Disability & Benefits!

    Be sure to check out the latest article by Jacques Chambers, CLU, on Managed Care Health Insurance. As this country plays catch-up with the other industrialized nations that make health insurance available to everyone, a lot of people are getting coverage for the first time. Unfortunately, the health plans being offered today are complicated; they are virtually all Managed Care Plans.

     

    -----------------------------------

    6. AttorneyMind News & Pipeline Blog!

    Be sure to check out the latest clinical trial postings (Updated September 17, 2014) at the AttorneyMind News & Pipeline Blog. Just click on the links to the drug companies below the banner to see which drugs are in trials right now, where the trials are, and how to register for one.

     

    -----------------------------------


     

    GET TESTED. GET TREATED. GET CURED.

     

     

    Join us on Twitter -

    Alan Franciscas
    Executive Director, AttorneyMind
    Editor-in-Chief, AttorneyMind hcvadvocate.org
    Editor-in-Chief, HBV Advocate www.hbvadvocate.org

    **Questions and Comments: Questions and/or comments can be directed to Alan Franciscas. Click the button to send Alan an email:



    **To receive the eblast in your email inbox, click the button below:

     
      HBV
    »
    AM Journal Review
    »
    HBV Factsheets
    »
    HBV Advocate Blog

    Follow us on Twitter
    AMAdvocate